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Abstract-This article discusses the role of economic appraisal in insurance based health care systems, 
taking the case of the Netherlands as an example. The public health insurance system in this country is 
governed by the Health Insurance Executive Board, which policies are firmly based on the results of 
economic appraisal. Furthermore, reimbursement policies regarding pharmaceutical products are de- 
scribed, emphasizing again the position of information from economic appraisal in these policies. The 
article concludes with the identification of some trends in health policy and in the way it is supported by 
economic appraisal studies. 
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1. INTRODUCTION 
Countries exhibit a considerable diversity of health 
care institutions and it is therefore not instructive to 
conduct a general discussion on the role of economic 
appraisal in health care policy. Indeed policies to 
guide the diffusion of health care technologies are 
quite different across health care systems and involve 
quite different actors. Hurst [l] suggests that health 
care systems can be described as comprising seven 
different mixtures of major subsystems of finance and 
delivery of health care. One distinction is related to 
the finance side and consists of three categories: out 
of pocket payment for health care, voluntary or 
private health insurance usually with choice of in- 
surer and compulsory or public health insurance, 
usually without effective choice of insurer. The latter 
two categories may be combined with one of three 
methods of paying providers: indirect payment of 
providers through reimbursement of patients, direct 
payment of providers by contracts and direct pay- 
ment of providers by global budget and salaries in a 
vertically integrated system. These characteristics in 
finance and delivery determine the degree and way of 
government regulation in these health care systems, 
either centralized or decentralized, and, as often in 
public insurance systems, with a delegation of power 
to quasi-governmental institutions. 
Depending on the character of the system and the 
actors involved in health policy the role of economic 
*Paper prepared for an EC Workshop on From Results IO 
Action: the Role of Economic Appraisal in Developing 
Policy for Health Technology, Heraklion, Crete, 8-10 
October 1992. 
evaluation will be different. Its role will be more clear 
when firm regulatory mechanisms are in place than in 
the case of a decentralized system where contracts 
between local financers and local providers determine 
the degree of diffusion of medical technologies. The 
specifics of resource allocation in a particular health 
care system may even determine the type of economic 
analysis needed. The perspective from which a study 
is undertaken differs according to whether central 
government or a local health care insurer is the 
principal user of the results, and in a competitive 
environment one tends to rely on cost-benefit analysis 
(willingness to pay determining the value of out- 
come), while in a socialized system cost-effectiveness 
or cost-utility analysis is more relevant. In Section 2 
we will discuss the options for control in a compul- 
sory health insurance system as is the dominant mode 
in central Europe. 
In Sections 3-5 we will consider the Dutch system, 
which key feature is also compulsory social health 
insurance. Under this system the whole population is 
insured for chronic care and about 60% of the 
population is compulsorily insured for acute care. 
The remainder of the population relies on voluntary 
insurance for acute care. Under the public insurance 
systems the GP’s are paid by capitation, specialists 
mainly by fee for service and hospitals by per diem 
payments under a global budget, which is determined 
through a budget formula and based on negotiations 
with local financers regarding variable costs. Private 
insurance reimburses patients who are billed on the 
basis of fee for service. Price and quantity of health 
care services financed through either insurance sys- 
tem are closely regulated by quasi-governmental 
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institutions. One of these is the Health Insurance 
Executive Board (HIEB), which is responsible for 
governing and controlling the public insurance sys- 
tem. From the mid eighties onward the Board’s 
policy has been to use the results of economic evalu- 
ation in a variety of ways, which will be discussed in 
Section 3. 
In Section 4 special attention will be given to the 
role of economic evaluation in promoting rational 
utilization of medicines. In contrast to the situation 
in other countries (compare the guidelines in Aus- 
tralia [2] and Ontario) there is not yet an official 
policy positioning economic evaluation in this area. 
We will give a number of examples, however, where 
the results of such studies have been quite influential. 
In Section 5 we will briefly touch on future develop- 
ments within the Dutch health care system and their 
likely consequences for the role of economic evalu- 
ation in health policy. 
Finally, in Section 6 we will identify a number of 
common problems related with the use of results of 
economic evaluation in health policy and formulate 
some lessons to be learned. 
2. ECONOMIC APPRAISAL AND HEALTH POLICY 
Economic evaluation may concern a technology in 
the early phase of its diffusion or one which diffusion 
has already progressed. In the former case regulation 
can be of a more directive nature, but the economic 
appraisal may be limited by lack of data. In the latter 
case more reliable data will be available, but it may 
be more difficult to influence the use of an established 
technology. Table 1 states the options for control of 
the diffusion of medical technologies, which may be 
supported by the results of an economic appraisal. 
Note that these are all regulatory mechanisms, which 
should be enforced during the early phase of the life 
cycle of a new technology. To improve the rational 
use of existing technologies incentives should be 
incorporated in the system, such as prospective reim- 
bursement of hospitals forcing management to install 
internal budgeting procedures and incentives towards 
efficiency for budget holders. 
Table 1 suggests that economic appraisal may 
support the operation of all regulatory mechanisms 
mentioned with the exception of pre-market controls 
for drugs and devices. Efficacy and safety are the 
main criteria for deciding on admittance of a technol- 
ogy into the market and there are no compelling 
arguments to add any other criteria. In many 
countries decisions on instituting national screening 
programmes are supported by evidence from econ- 
omic studies, and indeed more so than those on 
curative programmes. For instance, more than 90% 
of the recent Medline-literature on ‘costs’ and 
‘cancer’ refers to screening topics. Reimbursement 
decisions on new curative interventions are only 
occasionally supported by economic analysis, while in 
many countries economic studies have influenced 
reimbursement decisions concerning medicines. 
Economic appraisal may play a role in pricing of 
medicines, but this depends on the general pricing 
policies in a health care system and relates to the way 
in which reimbursement decisions are based on econ- 
omic arguments. For instance, if no pricing policy 
exists, rational use of medicines can still be promoted 
through the use of economic indicators, which are 
themselves dependent on price, in reimbursement 
decisions. And finally, licensing policies concerning 
for instance advanced equipment like MRI may 
benefit from economic analysis, especially when stud- 
ies on economies of scale are incorporated in such 
analysis. 
As we will see below these regulatory mechanisms 
are all used and supported by economic appraisal in 
Dutch health care policy, with the notable exception 
of pricing of medicines. Most prominent in this 
respect are policies as developed within the Health 
Insurance Executive Board, and these will be dis- 
cussed in the next section. 
3. THE GENERAL POLICY OF THE HEALTH INSURANCE 
EXECUTIVE BOARD 
To explain the HIEB policy it is important to note 
that compulsory health insurance in the Netherlands 
is regulated by two laws: the Compulsory Health 
Insurance Act and the General Act on Extraordinary 
Medical Expenses, the first covering about 60% of 
the population and the latter the whole population. 
The criterion used to judge whether a particular new 
intervention should be added to the existing benefit 
packages under these laws has always been whether 
such new intervention was generally accepted by the 
medical profession. Confronted with an increasing 
gap between financial resources and opportunities 
from advancing medical technology, the HIEB devel- 
oped a two-stage strategy in the mid eighties to make 
a halt to the systematic extension of the benefit 
Table 1. ODtions for control of the diffusion of medical technolozies 
Regulatory mechanism Role of economic appraisal 
Pre-market controls for drugs and devices 
Reimbursement from public insurance funds 
-preventive programs ++ 
-new curative interventions + 
-medicines (NCE’s) ++ 
Pricing of medicines + 
Licensing of advanced facilities + 
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packages and to rationalize policy making in this 
matter. 
First, the HIEB decided to designate certain tech- 
nologies as emerging and to control their diffusion. 
For these technologies a three-step procedure was 
adopted: diffusion of the new technology should be 
limited and controlled, a medical technology assess- 
ment should be carried out simultaneously, and 
finally, a decision about inclusion of the technology 
in the benefit packages should be made on the basis 
of the results of such medical technology assessment. 
This procedure was followed for heart transplant, 
liver transplant, breast cancer screening and in vitro 
fertilization. Based on the results of those studies the 
HIEB could give well documented advice to include 
heart transplants in the benefit package, to postpone 
such a decision in case of the liver transplant, to 
introduce breast cancer screening for women older 
than 50 years of age and to postpone the final 
decision on in vitro fertilization until there is more 
clarity as to the place of in vitro fertilization in the 
benefit package of the new insurance system [3]. 
Although this policy had been successful, it was 
based on the assumption that central decision making 
concerning the flow of money could decisively inter- 
fere in the process of the introduction of a new 
medical technology. In some cases it turned out that 
this was difficult, especially when the co-operation of 
the clinicians was lacking. For instance, the introduc- 
tion of the heart transplant programme was some- 
what rapid as one university hospital just started 
doing their own heart transplants without formal 
approval of the government. Secondly, one became 
aware that clinicians should be made familiar with 
the idea that evaluation is a natural step before 
introduction at a wider scale and that participating in 
such evaluation sometimes provide the only opportu- 
nity to provide a new intervention or programme (as 
was the case with the technologies mentioned above). 
And finally, not only the question which technique to 
in- or exclude from the benefit package should be 
posed, but also for which indications a particular 
technology would be cost-effective? 
Therefore, the HIEB choose to initiate yet another 
strategy directed to a more thorough investigation of 
the possibilities to increase cost-effective and appro- 
priate use of new and existing forms of medical care. 
This strategy focuses more on the cost-effective appli- 
cation of technologies and procedures and should 
therefore be targeted especially to the clinicians, who 
are responsible for resource allocation at the patient 
level. This strategy led to a change in both Acts in the 
sense, that the concept of a generally accepted stan- 
dard for the medical profession was extended towards 
a standard, which is to be determined through debate 
between the medical profession and the financers of 
health care including the government. Application of 
such newly defined standard to each case would imply 
a great need for cost-effectiveness analyses. 
In 1988 the HIEB, together with the Ministries of 
Health and of Education and Science, started a 
programme of ‘investigative medicine’. Investigative 
medicine is a clinical evaluation programme concern- 
ing new and established medical technologies, provid- 
ing more opportunity for supporting policy decisions. 
Such policy decision could concern: 
- acceptation of a new medical technology or 
procedure or withdrawing an existing one as a 
benefit in kind in the Compulsory Health In- 
surance Act; restriction of the indication to qual- 
ify for a benefit in kind. 
-improving the efficiency or effectiveness of the 
use of a medical procedure by means of legis- 
lation or through-agreement on a ‘protocol’; 
- a planning decision in connection with the Hospi- 
tal Provisions’ Act. 
Each year 36 million Dutch guilders are available 
to allocate to projects in this programme and re- 
searchers/clinicians may each year apply for funds by 
submitting a proposal which should follow the fol- 
lowing general criteria: 
-the results of the projects should contribute to 
decision-making concerning a particular health 
care intervention; 
-a well-designed study plan to compare such 
intervention with the most cost-effective alterna- 
tive; 
- a thorough evaluation of both effectiveness and 
costs and, if appropriate, also judicial, organiz- 
ational and ethical aspects; 
- a three-years research period. 
Excluded from the ‘investigative medicine’ initiat- 
ive are fundamental research, improvement of treat- 
ment without evaluation and clinical trials with new 
pharmaceuticals and new equipment. For new medi- 
cal technologies and procedures efficacy should be 
proven; for established technologies the question of 
effectiveness could be part of the evaluation. 
After 5 years experience with the programme a 
number of positive conclusions can be made, as the 
first studies have been finished last month and others 
will follow soon. Many ongoing studies have already 
produced publications. It can be foreseen now that 
studies in this programme will contribute to the 
decisions of the government and to professional 
agreement in formulating treatment protocols, as is 
for instance the case with diagnostics of thrombosis 
which will decrease 66% of present hospital treat- 
ment, which involves many false positives. Another 
positive consequence is the controlled introduction of 
for instance pancreas and lung transplantation and 
ECMO. A third contribution of studies in this pro- 
gramme is in decision making about the indication- 
area of growth factors (GM-CSF) and autologous 
bonemarrow transplantations. 
Furthermore, medical technology assessment as an 
interdisciplinary effort flourishes in the Netherlands, 
due both to the funding programme itself and to the 
increasing interest from clinicians and policy makers. 
This field of investigative medicine has gained in 
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importance and in status. On the other hand, there 
seems to be an overemphasis on high technology as 
new medical interventions are being evaluated in 
more than 80% of the cases, so less work is done on 
established technologies. Furthermore, 70% of the 
proposals concern therapy and 30% concern diagnos- 
tics. The fields of oncology, cardiovascular disease, 
organ transplantation, neurology and gynaecol- 
ogy/obstetrics dominate. But there is some evidence 
that dissemination of the result of this programme is 
relatively good as peer clinicians are involved in these 
projects from the beginning. In the future, the Com- 
mittee for Investigative Medicine wants to combine 
the top-down and bottom-up approach by selecting 
some topics for evaluation themselves and asking for 
tenders from research institutes. 
4. THE POLICY REGARDING MEDICINES 
Health policy makers may influence the use of 
medicines in health care in a variety of ways. In most 
countries there are barriers to entrance into the 
market (pre-market controls), there may be restric- 
tions to reimbursement, there may be an active 
pricing policy, and there may be a variety of indirect 
ways of influencing the behaviour of the prescribing 
physician. And there are sometimes other objectives 
than improving the efficiency of health care pro- 
grammes, e.g. when countries want to foster invest- 
ment in plants and research. In discussing these 
options, the role of economic evaluation and the 
Dutch experience in this context, it is useful to make 
a distinction between extramural use of medicines 
and the use of medicines within the hospital. For both 
types of medicines the registration procedure is simi- 
lar. As in most countries the only criteria in the 
context of registration are ‘efficacy’ and ‘safety’. 
Economic evaluation is not foreseen to play a role in 
this phase. 
Regarding medicines used in an ambulatory setting 
in the Netherlands there exists an open system of 
reimbursement of medicines, meaning that registered 
drugs are in principle being reimbursed. Sweden and 
the Netherlands are generally considered as countries 
with a rather liberal system with respect to prescrib- 
ing [4]. Increasingly, however, medicines are allocated 
to a list (Appendix 3, agreement pharmaceutical care 
in public health insurance), where there are restric- 
tions to the use of medicines in this respect. These 
restrictions may relate to certain indications, but may 
also relate to the discipline of the prescribing phys- 
ician. Also for a number of medicines on this list, 
permission to use them should be granted from the 
public insurance agency in advance. This list contains 
products like interferon, growth factors and erythro- 
poietin (EPO), which are costly as they are produced 
by DNA recombinant analysis. Examples of drugs in 
this list are for instance AZT and the new cholesterol 
lowering agents. In some cases where no permission 
a priori is needed such as in the case of cholesterol 
lowering drugs, the HIEB is monitoring sales of these 
medicines at a global level comparing a priori expec- 
tations based on epidemiological analysis and actual 
sales in the market. If the discrepancy becomes too 
large, a procedure to require permission in advance 
for prescribing these cholesterol lowering drugs may 
be instituted. 
Economic evaluation has played and will play a 
role in this policy of conditional reimbursement. For 
instance, at the time of deciding about reimbursement 
of Zocor (the new cholesterol lowering agent of 
MSD) the HIEB had at its disposal an advice by the 
Health Council and an economic evaluation carried 
out at the initiative of the producer of the drug, 
MSD. The results of this study were taken into 
account when deciding on the conditions for reim- 
bursement of Zocor. The HIEB is now discussing a 
change from an ‘open system’ to a ‘closed system’, 
meaning that new innovative drugs (New Chemical 
Entities) will only be reimbursed after an explicit 
decision by the Board (followed by approval of the 
Ministry of Health, Welfare and Cultural Affairs). It 
is foreseen that economic appraisal will support such 
decision making process and that guidelines about 
the format of such appraisal (as in Australia and 
Ontario) will be issued. 
Another issue in reimbursement is the introduction 
in 1991 of a new reimbursement system for medicines 
based on the concept of reference prices. For classes 
of medicines with the same therapeutic effectiveness 
a reference price will be determined and the insured 
will have to pay the difference between the actual 
price and the reference price. This reference price is 
chosen in such a way that there is enough opportunity 
for the insured to receive proper medication without 
any co-payment. One of the assumptions underlying 
this reference price system is that price increases 
because of innovation by way of introducing me-too 
products can be mitigated. Furthermore, the system 
is believed to make physician prescribers more aware 
of the prices of medicines. As a consequence of 
introducing this system the price index of drugs and 
pharmaceutical products decreased with an initial 
3%. In some sectors, however, producers and im- 
porters of drugs increased their prices considerably 
(anti-conceptives) creating a situation of considerable 
co-payment. Prescribers, pharmacists and insured 
reacted by changing over to cheaper products, which 
made the producers and importers, who initially 
increased their prices, to reduce them again toward or 
just under the reference price. In general one can 
observe an increasing market share of generic and 
parallel imported drugs in 1992. Sofar, there has not 
been a role for economic appraisal in regard to this 
reference price system of reimbursing drugs. Some 
pharmaceutical companies, however, are in the pro- 
cess of assembling economic evidence, trying to 
demonstrate that their product is different in its 
cost-effectiveness profile from the other drugs, with 
which they are placed in the same reference group. 
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There is no evidence yet that such arguments may 
change the position of a particular drug in the 
reference price system. 
By far the most important contribution to increas- 
ing the efficiency of drug use lies in the indirect ways 
of influencing prescribing behaviour of physicians. 
The role of individual public health insurance 
agencies is rather limited as they have few opportuni- 
ties to create incentives for physicians to be efficient 
(for instance, they can not end a contractual relation- 
ship with a physician). One of the items in the plans 
for a revision of the Dutch health insurance system 
is to introduce more competition between providers 
and free contracting of health insurance agencies with 
those providers. This leaves more opportunity for 
financers to incorporate incentives for efficiency in 
contracts with providers. 
Another important innovation is the start of phar- 
macotherapeutic commissions, in which pharmacists 
and prescribing physicians systematically discuss pro- 
tocols for prescribing drugs. During an experiment 
with such commission in a particular region about 
87% of general practitioners participated in the 
discussions, as well as 96% of the pharmacists. 
Reports about cost-effective drug use may be inputs 
in such discussion. Furthermore, the HIEB publishes 
every year a pharmacotherapeutic advice concerning 
the price/quality ratio of medicines to inform the 
practitioners. 
Hospital drugs are normally reimbursed from hos- 
pital budgets as is the case with other expenditure 
within the hospital. However, it is possible to obtain 
an additional budget for costly drugs or biotech 
products. Such addition to the budget was given for 
erythropoietin (EPO) in relation to its use for dialysis 
patients. In such case there is an earmarked flow of 
money to the hospital specific for the use of EPO in 
dialysis patients. In this case economic appraisal only 
played a minor role, but the HIEB secretariat is 
assembling information on the impact of EPO on 
quality of life in order to continuously evaluate their 
policy in this respect. Because of the high costs of 
some new biotech products like G-CSF pharmaceuti- 
cal companies are assembling economic data to facili- 
tate their discussions with the HIEB on the position 
of their products in hospital care. 
From the observations above one may conclude, 
that there is a trend towards a greater role of 
economic appraisal in health policy decisions on 
the reimbursement of drugs and biotech products. 
The HIEB secretariat is now developing its policies 
for the nineties and considering a fundamental 
change towards formalizing the role of economic 
evaluation in this area. The outcome of the discussion 
is possibly that only medicines that are innovative 
and offer a really effective therapy should be reim- 
bursed. In other cases a medicine will be clustered in 
the reference price system of will be excluded for 
reimbursements. 
5. DECENTRALIZATION IN HEALTH POLICY 
In 1988 the Dutch government decided to radically 
reform the financial structure and the organization of 
the health care system. Two major components of 
this reform are the introduction of a national health 
insurance scheme and regulated competition among 
insurers and among providers [5]. Execution of this 
plan started in 1989 and was expected to be com- 
pleted in 1994. The latter will not be achieved since 
there is political debate on whether and, if so, in what 
form the plans should continue to be carried out. 
With respect to health insurance the division between 
compulsory insurance under the Health Insurance 
Act, private insurance and the insurance schemes for 
public servants is planned to disappear. Instead, there 
will be a national health insurance scheme offering a 
relatively wide range of benefits. Some first steps 
towards such insurance system are being set and more 
flexibility is introduced concerning the way of offer- 
ing these benefits to the insured population. For 
instance, in the old system specific types of treatment 
to be delivered by specific health care providers were 
narrowly circumscribed in the benefit package, while 
in the new system insurers are free to substitute one 
form of care for the other as long as these are serving 
similar purposes. 
This planned health reform can be characterized 
as a change from a highly government regulated 
system towards a system where resource allocation is 
mainly determined through contracting of individual 
providers and insurers. Central government regu- 
lation will become less important and so will the need 
to support these policies with evidence from econ- 
omic appraisal. Instead, we will see a growing need 
for this kind of information with the regional and 
local parties in health care. Indeed, Henshall and 
Drummond [6] argue that competitive forces may 
encourage individual parties to consider cost- 
effectiveness information. On balance, however, we 
predict that it will take some time before the new 
parties in health care are able to appreciate the 
benefits of economic appraisal and position the out- 
comes of such studies in their own policy-making 
processes. So the level of activities in economic 
appraisal may fall! First, problems can be expected 
when dealing with medical technologies, which have 
a supra-regional characteristic and can only meaning- 
fully be tackled at a national level. Furthermore, 
individual insurers or health care organizations may 
find it difficult to finance economic appraisal studies 
when these yield results of a more general value than 
only for one particular insurer or health care organ- 
ization. A free rider problems emerges when such 
information is also freely available to others, and if 
this is not the case and the information is clearly 
marked as having a commercial value, there will be 
obvious problems with the dissemination of such 
information. And finally, the danger of relying too 
much on market forces is that the role of consumer 
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preferences will become dominant, and this may 
conflict with utilitarian values as seen from society’s 
perspective such as cost-effectiveness [7]. Maybe 
patient and consumer organizations may step in and 
resume some of the responsibilities that are being left 
by the government. If so, they may become more 
important in initiating economic appraisal studies 
and promoting dissemination of results. In con- 
clusion, there are great uncertainties about the role of 
economic appraisal in health policy when the reform 
plans will be actually executed. 
6. OBSERVATIONS AND CONCLUSIONS 
Some observations from the Dutch experience as 
described above can be made and some tentative 
conclusions can be drawn: 
- Dutch policies concerning the initiation of econ- 
omic appraisal studies seem to converge towards 
a mixed top-down bottom-up approach. The 
former (topdown) has the clear advantage of 
positioning economic appraisal firmly in health 
care policy as in the case of the initial HIEB 
strategy, while the latter (bottom-up) has the 
advantage of being better integrated in the clini- 
cal and research community which may further 
the dissemination of the results of economic 
appraisal among clinicians. Furthermore, the 
HIEB policies and, particularly, the ‘investigative 
medicine’ program have contributed consider- 
ably to the development of expertise in economic 
appraisal and, more generally, in medical tech- 
nology assessment and to the cooperation be- 
tween clinicians and evaluation-researchers; 
- The role of economic appraisal in deciding on the 
reimbursement of drugs and biotech products 
will become more important and a similar devel- 
opment towards formalizing this role as in Aus- 
tralia and Ontario is expected in the coming 
years. This is not only in line with EC-transpar- 
ency rules, but would also provide a clear signal 
to industry to strive towards cost-effective prod- 
ucts and to assemble data on cost-effectiveness at 
an early stage [6]. There is a tendency to reim- 
burse only really innovative medicines which 
offer new therapeutic opportunities as well as 
those medicines which have a favourable cost- 
effectiveness profile; 
-The timing of a study has shown to be an 
important issue. Looking back at the initial 
HIEB initiatives for economic appraisal, the liver 
transplant study was initiated too early as the 
technology was still developing, while the IVF 
study was probably too late to achieve maximum 
momentum in policy. An early warning function, 
as is assumed by the Dutch Health Council, 
would contribute to gaining time for selecting the 
right topics and determining the timing for carry- 
ing out appraisals. Initiating a study should be 
such as to maximize its contribution to rational 
policy making and not to merely slow down the 
diffusion of a technology. Recently, the Dutch 
government, advised by the HIEB, has chosen for 
an (optional) moratorium for new technologies 
for the time, which is needed to perform a 
cost-effectiveness study in the context of the 
‘investigative medicine’ programme. 
- a shift can be observed from studies dealing with 
the cost-effectiveness of a specific intervention 
per se towards studies on the cost-effective use of 
such intervention in specific patient groups. The 
latter is sometimes referred to as ‘studies on 
appropriate care’, but we would object to this 
term if it would be defined as ‘what doctors seem 
appropriate’. Indeed, consensus should be 
reached among all parties in health care about 
what is appropriate and what not, and economic 
appraisal is a powerful tool to assist in this 
debate. 
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